Dual-targeted microspheres reshape the metabolic-immune microenvironment to reverse post-embolization dilemmas in hepatocellular carcinoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41985455.
- Also identified by DOI 10.1016/j.xcrm.2026.102748.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transarterial embolization (TAE) efficacy in hepatocellular carcinoma (HCC) is limited by post-embolization hypoxia-driven angiogenesis and metabolic reprogramming. To address this, we develop pH-responsive gelatin microspheres (GMs) encapsulating zinc sulfide (ZnS) nanoparticles (ZnS-encapsulated gelatin microspheres [ZnS@GMs]) for the dual delivery of hydrogen sulfide (H<sub>2</sub>S) gas and Zn<sup>2+</sup> ions. ZnS@GMs inhibit tumor growth through suppression of the hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) axis and glycolytic metabolism, alongside promoting vascular normalization and immune activation. Mechanistically, H<sub>2</sub>S disrupts mitochondrial respiration, increasing oxygen levels and destabilizing HIF-1α, whereas Zn<sup>2+</sup> inhibits hexokinase and lactate dehydrogenase, depleting ATP and biosynthetic intermediates. Furthermore, ZnS@GMs induce immunogenic cell death, which triggers dendritic cell maturation, cytotoxic T cell infiltration, and macrophage repolarization, thereby enhancing the efficacy of anti-PD-1 therapy. In a rabbit orthotopic liver tumor model, intra-arterial infusion of ZnS@GMs confirms potent antitumor effects and effective embolic performance. This work establishes ZnS@GMs as a multifunctional platform to overcome TAE resistance in HCC.